LivaNova (NASDAQ:LIVN) Updates FY25 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY25 earnings guidance on Tuesday. The company provided EPS guidance of $3.65-3.75 for the period, compared to the consensus EPS estimate of $3.66. The company issued revenue guidance of ~$1.316-1.329 billion, compared to the consensus revenue estimate of $1.33 billion. LivaNova also updated its FY 2025 guidance to 3.650-3.750 EPS.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $75.00 price target on shares of LivaNova in a research report on Tuesday, January 28th. Mizuho decreased their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. Robert W. Baird increased their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $69.17.

LivaNova Stock Performance

NASDAQ:LIVN opened at $46.53 on Tuesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The firm has a market cap of $2.53 billion, a price-to-earnings ratio of 115.61 and a beta of 1.00. LivaNova has a 52-week low of $43.15 and a 52-week high of $64.47. The business’s fifty day moving average is $47.94 and its 200 day moving average is $49.64.

Insider Buying and Selling at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. This trade represents a 14.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.27% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.